The strategy for long-term growth is built on maximizing the potential of the strong commercial platform on the US market. The lead product, ZUBSOLV®, which is an important cash generator, has paved the way for investments in novel pharmaceutical candidates and evidence-based digital therapies with the aim to build a broader and stronger company.
Strategic priorities
1. Broadening the portfolio of commercial products to be promoted by our US Pharma and Digital Therapeutics business areas
2. Maintaining ZUBSOLV® profit contribution and ensure it is sustainable and growing over time
3. Establishing a new profitable business area within Digital Therapeutics and create a new platform for growth
4. Enhancing the development pipeline in pharma, led by OX124, an opioid overdose rescue medication, and the novel amorphOX™ platform